Canada's opioid epidemic continues, with the latest news coming from Ontario. Currently, opioid misuse is the third leading cause of death in the province.
The newest measures to stem the tide of addiction include theappointment of Dr. David Williams, Ontario’s Chief Medical Officer of Health, as Ontario’s first-ever Provincial Overdose Coordinator. His office will launch a new surveillance and reporting system to better respond to opioid overdoses in a timely manner and inform how best to direct care.
The province will also develop standards for opioid prescription to prevent overprescription--these will be released in 2017-2018. Other controls will be introduced, as well: next year, high-strength versions of long-acting opioids will be de-listed from the Ontario Drug Benefit Formulary. Access to the overdose medication naloxone will also be expanded and offered free of charge. One change that has already taken effect is strictercontrols on the prescribing and dispensing of fentanyl patches. Patients are now required to return used fentanyl patches to their pharmacy before more patches can be dispensed.
Interestingly, there have been no mentions of ceasing or even reducing opioid production--only controlling access and establishing more pain clinics to put a bandage over the problem. With the impending Health Canada measures to treat natural products as drugs, it will be increasingly difficult for customers to distinguish the two. Will customers choose the natural option without side effects, or the allopathic option with its risks?
Avoiding opioids is the safest option. Doctor's Choice offers several natural pain relief products, including DMSO and Sweet Relief MSM Cream. These products have greatreviews, and we recommend them to anyone seeking natural pain relief without the damaging effects of opioids.
With over 10 years of experience, Bond Consulting is a leader in the SR&ED industry. The SR&ED program is designed to support innovative companies with cash reimbursements from the Canadian Government due to their private R&D efforts. (www.bondconsulting.ca)